Published in Angew Chem Int Ed Engl on January 18, 2002
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76
Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem (2013) 2.02
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A (2007) 1.76
Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc (2009) 1.72
Inhibiting HIV fusion with a beta-peptide foldamer. J Am Chem Soc (2005) 1.55
Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J R Soc Interface (2006) 1.53
Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain. J Am Chem Soc (2011) 1.49
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33
A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1. Antimicrob Agents Chemother (2007) 1.31
Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad Sci U S A (2004) 1.30
Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A (2004) 1.22
Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl (2015) 1.17
Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A (2009) 1.14
Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactions. Bioorg Med Chem (2012) 1.03
Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41. J Med Chem (2011) 1.00
Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain. Retrovirology (2011) 0.99
Development of small molecules designed to modulate protein-protein interactions. J Comput Aided Mol Des (2006) 0.97
Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling. J Am Chem Soc (2012) 0.95
Examination of a fusogenic hexameric core from human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptad repeat 1 region. J Virol (2006) 0.94
Comprehensive peptidomimetic libraries targeting protein-protein interactions. Acc Chem Res (2012) 0.93
Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Bioorg Med Chem Lett (2009) 0.90
Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library. Bioorg Med Chem Lett (2012) 0.89
Broad distribution of energetically important contacts across an extended protein interface. J Am Chem Soc (2011) 0.88
Identification of a beta3-peptide HIV fusion inhibitor with improved potency in live cells. Bioorg Med Chem Lett (2009) 0.87
Evaluating minimalist mimics by exploring key orientations on secondary structures (EKOS). Org Biomol Chem (2013) 0.85
Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues. Chembiochem (2009) 0.85
Amphipathic properties of HIV-1 gp41 fusion inhibitors. Curr Top Med Chem (2011) 0.84
Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. J Med Chem (2015) 0.84
Islet amyloid-induced cell death and bilayer integrity loss share a molecular origin targetable with oligopyridylamide-based α-helical mimetics. Chem Biol (2015) 0.83
Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions. F1000Res (2014) 0.81
Synthesis of the phenylpyridal scaffold as a helical peptide mimetic. Chemistry (2010) 0.81
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction. Int J Pept Res Ther (2006) 0.81
Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. Viruses (2013) 0.78
Synthesis of a tetrasubstituted tetrahydronaphthalene scaffold for α-helix mimicry via a MgBr2-catalyzed Friedel-Crafts epoxide cycloalkylation. Org Lett (2013) 0.76
Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. Curr Top Med Chem (2016) 0.75
Facile iterative synthesis of 2,5-terpyrimidinylenes as nonpeptidic alpha-helical mimics. J Org Chem (2010) 0.75
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
Label-free immunodetection with CMOS-compatible semiconducting nanowires. Nature (2007) 5.25
RePS: a sequence assembler that masks exact repeats identified from the shotgun data. Genome Res (2002) 4.35
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Detecting protein-protein interactions with a green fluorescent protein fragment reassembly trap: scope and mechanism. J Am Chem Soc (2005) 2.95
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest (2008) 2.87
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76
Purgative bowel cleansing combined with simethicone improves capsule endoscopy imaging. Am J Gastroenterol (2007) 2.73
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed Engl (2005) 2.65
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Water gelation by small organic molecules. Chem Rev (2004) 2.45
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol (2011) 2.31
Systematic exploration of essential yeast gene function with temperature-sensitive mutants. Nat Biotechnol (2011) 2.26
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (2007) 2.22
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Synthetic non-peptide mimetics of alpha-helices. Chem Soc Rev (2007) 2.04
Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation (2004) 2.04
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology (2005) 2.03
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev (2008) 2.00
Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem (2005) 1.99
Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol (2006) 1.85
Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods (2008) 1.84
Two new complete genome sequences offer insight into host and tissue specificity of plant pathogenic Xanthomonas spp. J Bacteriol (2011) 1.80
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem (2004) 1.76
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. PLoS One (2010) 1.75
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol (2005) 1.70
A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol (2008) 1.70
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun (2004) 1.67
HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des (2007) 1.66
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol (2004) 1.62
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. Microbes Infect (2013) 1.59
Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis. Neurology (2014) 1.59
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.58
HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem (2007) 1.58
Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res (2002) 1.57
Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew Chem Int Ed Engl (2003) 1.55
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer (2010) 1.54
Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J R Soc Interface (2006) 1.53
Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc (2002) 1.50
Research and development of universal influenza vaccines. Microbes Infect (2010) 1.49
Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew Chem Int Ed Engl (2005) 1.49
Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs (2008) 1.48
Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics. Curr Opin Chem Biol (2010) 1.47
Long-term cardiovascular risk in women prescribed fertility therapy. J Am Coll Cardiol (2013) 1.46
Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J Am Chem Soc (2005) 1.46
Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ (2010) 1.44
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem (2002) 1.43
Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides (2003) 1.41
Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr (2003) 1.40
Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem (2004) 1.40
The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem (2010) 1.39
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.38
FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Am Chem Soc (2006) 1.36
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine (2006) 1.36
Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem (2007) 1.34
Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. J Am Chem Soc (2005) 1.34
Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides. Angew Chem Int Ed Engl (2007) 1.34
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res (2013) 1.33
In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 1.33
Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol (2007) 1.32
Microbicides: stopping HIV at the gate. Lancet (2006) 1.31
Solution structure of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid. J Biol Chem (2008) 1.30
Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice. Hepatology (2010) 1.29
Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A (2011) 1.28
A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect (2012) 1.28
Stem cell-delivery therapeutics for periodontal tissue regeneration. Biomaterials (2012) 1.27
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol (2006) 1.27
An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J (2010) 1.26